dm+d

410965002

New Medicines

ZiborPrevention of thromboembolism in patients undergoing orthopaedic surgery and prevention of clotting in the extracorporeal circuit during haemodialysis

Information

Zibor
New molecular entity
Rovi
Not Known

Development and Regulatory status

Launched
Launched
None
September 2008 and September 2021
Sep 21Rovi re-launches Zibor in the UK. It is licensed for prevention of thromboembolic disease in patients undergoing orthopaedic surgery, and prevention of clotting in the extracorporeal circuit during haemodialysis. It is available in a strength of 12,500 iu anti-Factor Xa activity per ml, in pre-filled syringes (price for 10 x 0.2ml=£20.90) and in a strength of 17,500 iu anti-Factor Xa activity per ml, in pre-filled syringes (price for 10 x 0.2ml=£33.96) [2].
Feb 12Zibor is no longer available in the UK [2].
Sep 08Launched in the UK [1].

Category

A low molecular weight heparin (LMWH) obtained by depolymerization of heparin sodium from porcine intestinal mucosa. Its mean molecular weight (MW) is approximately 3,600 daltons.
Variable, as several indications
Prevention of thromboembolism in patients undergoing orthopaedic surgery and prevention of clotting in the extracorporeal circuit during haemodialysis
Subcutaneous injection

Evidence based evaluations

SPC